NorthStar Medical Radioisotopes and Convergent Therapeutics have announced an expanded strategic collaboration for CONV01-α, a new treatment for prostate cancer. A lead asset of Convergent, CONV01-α is a prostate-specific membrane antigen-targeted monoclonal antibody attached to Ac-225. The gold standard of business intelligence.
Under the contract manufacturing services agreement, NorthStar will supply Convergent with environmentally preferred, high purity non-carrier-added Ac-225 to be used in CONV01-α. NorthStar will also leverage its new contract development and manufacturing facility to produce CONV01-α for Convergent’s clinical trials. NorthStar will engage in research and development activities to further the development of CONV01-α and other assets from Convergent.
In March 2024, Convergent obtained clearance for an investigational new drug application from the US Food and Drug Administration for CONV01-α. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form This clearance enables Convergent to proceed with Phase II studies and broaden the clinical development of CONV01-α, both as a standalone therapy and in combination with .